In MDA-MB-231 breast cancer cells, 100 µM I3C for 48 h favored full-length 50-kDa cyclin E and increased the G1 DNA-content fraction. Elastase siRNA produced similar changes relative to transfection and scrambled-siRNA controls, supporting a contribution of elastase to this response without establishing an exclusive mechanism. [1]
Noncompetitive inhibition of human neutrophil elastase
Biochemical assay · Purified human neutrophil elastase with in vitro produced cyclin E or chromogenic MetS substrate [1]
Kinetic analyses using two substrates supported noncompetitive inhibition. The reported constants are Ki values, not cellular IC50 values. Cyclin E processing controls included DMSO, absence of elastase, and known elastase inhibitors (Figure 1B–C).
Literature-Reported Treatment Conditions
- Treatment concentration
- Cyclin E kinetic series: 0, 15, 25 and 50 µM I3C (Figure 3A–B). MetS series: 0, 25, 50 and 100 µM I3C (Figure 3C).
- Exposure duration
- Cyclin E assay: 5 min; chromogenic assay duration not established from retrieved main text.
- Method
- Cell-free enzyme assays
- Vehicle
- DMSO control
- Reported limits
- SI kinetic protocol not retrieved; replicate n and meaning of Ki ± terms not defined in the retrieved main text. Main Methods specifies 30 °C for cyclin E digestion whereas Figure 3 caption specifies 37 °C; no temperature-specific potency claim is made.
Methods and source locations
Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C
Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.
Results: I3C Acts as a Noncompetitive Inhibitor; Figure 3A–C and caption; main Methods: cyclin E processing assay
Inhibition of elastase-mediated cyclin E processing: Western blot densitometry of remaining 50-kDa cyclin E; Dixon plot analysis — Results: I3C Acts as a Noncompetitive Inhibitor; Figure 3A–C and caption; main Methods: cyclin E processing assay
Inhibition of chromogenic MetS hydrolysis by elastase: Spectrophotometric substrate hydrolysis; Dixon plot analysis — Results kinetic analysis; Figure 3C and caption
Elastase knockdown phenocopies I3C-associated cell-cycle effects
Cell-based study · MDA-MB-231 human breast cancer cells; transfection, scrambled-siRNA and elastase-siRNA controls [1]
I3C treatment and elastase knockdown each favored the 50-kDa cyclin E form and increased the G1 fraction. The combined condition retained an additional effect, consistent with elastase contributing to, rather than fully accounting for, I3C responses.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 µM I3C
- Exposure duration
- 48 h I3C exposure after 24 h siRNA/transfection period
- Method
- Treatment of transfection-control, scrambled-siRNA and elastase-siRNA groups, with or without I3C
- Vehicle
- DMSO
- Reported limits
- Full cell-culture details reside in SI, which was not retrieved. Figure 4C values are representative panel values; biological replicate n and uncertainty for those percentages are not specified in the retrieved main text.
Methods and source locations
Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C
Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.
Results: siRNA Knockdown of Cellular Elastase Levels; Figure 4A–C and caption; Methods: siRNA Knockdown of Cellular Elastase Levels
Cyclin E protein forms: Western blot; Hsp90 loading control — Figure 4B and caption; accompanying Results
G1 DNA-content fraction in representative flow-cytometry panels: Propidium iodide DNA-content flow cytometry — Figure 4C labels and caption
Binding to the WWP1 HECT domain
Biochemical assay · Fluorescently labeled recombinant His-WWP1 HECT wild type and F577/Y656A mutant [2]
Microscale thermophoresis showed binding to the wild-type HECT domain and weaker apparent affinity for the double mutant. Binding constants do not constitute catalytic IC50 values or prove cellular target selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Methods describes a two-fold I3C dilution series from 7.63 nM to 250,000 nM, mixed 1:1 with labeled WWP1.
- Exposure duration
- Measurement incubation duration not specified in the retrieved MST Methods.
- Method
- MST at 25 °C in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol
- Reported limits
- Independent replicate n, fitted uncertainty and a separate compound-only fluorescence control are not stated in the retrieved MST description. The dilution-series wording does not explicitly distinguish premix from final concentration, so no revised final range is inferred.
Methods and source locations
Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C
Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.
Results: Identification of indole-3-carbinol as a WWP1 inhibitor; Figure 5B and caption; Methods: Reagents; Protein labeling and microscale thermophoresis (MST) analysis
I3C binding to wild-type WWP1 HECT domain: Microscale thermophoresis using MONOLITH NT.115 — Results: Identification of indole-3-carbinol as a WWP1 inhibitor; Figure 5B and caption; Methods: Reagents; Protein labeling and microscale thermophoresis (MST) analysis
I3C binding to WWP1 HECT F577/Y656A mutant: Microscale thermophoresis; mutant comparator — Figure 5B and caption; Results identification of I3C as WWP1 inhibitor